It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
In current international classification systems (ICD-10, DSM5), the diagnostic criteria for psychotic disorders (e.g. schizophrenia and schizoaffective disorder) are based on symptomatic descriptions since no unambiguous biomarkers are known to date. However, when underlying causes of psychotic symptoms, like inflammation, ischemia, or tumor affecting the neural tissue can be identified, a different classification is used ("psychotic disorder with delusions due to known physiological condition" (ICD-10: F06.2) or psychosis caused by medical factors (DSM5)). While CSF analysis still is considered optional in current diagnostic guidelines for psychotic disorders, CSF biomarkers could help to identify known physiological conditions. In this retrospective, partly descriptive analysis of 144 patients with psychotic symptoms and available CSF data, we analyzed CSF examinations' significance to differentiate patients with specific etiological factors (F06.2) from patients with schizophrenia, schizotypal, delusional, and other non-mood psychotic disorders (F2). In 40.3% of all patients, at least one CSF parameter was out of the reference range. Abnormal CSF-findings were found significantly more often in patients diagnosed with F06.2 (88.2%) as compared to patients diagnosed with F2 (23.8%, p < 0.00001). A total of 17 cases were identified as probably caused by specific etiological factors (F06.2), of which ten cases fulfilled the criteria for a probable autoimmune psychosis linked to the following autoantibodies: amphiphysin, CASPR2, CV2, LGl1, NMDA, zic4, and titin. Two cases presented with anti-thyroid tissue autoantibodies. In four cases, further probable causal factors were identified: COVID-19, a frontal intracranial tumor, multiple sclerosis (n = 2), and neurosyphilis. Twenty-one cases remained with "no reliable diagnostic classification". Age at onset of psychotic symptoms differed between patients diagnosed with F2 and F06.2 (p = 0.014), with the latter group being older (median: 44 vs. 28 years). Various CSF parameters were analyzed in an exploratory analysis, identifying pleocytosis and oligoclonal bands (OCBs) as discriminators (F06.2 vs. F2) with a high specificity of > 96% each. No group differences were found for gender, characteristics of psychotic symptoms, substance dependency, or family history. This study emphasizes the great importance of a detailed diagnostic workup in diagnosing psychotic disorders, including CSF analysis, to detect possible underlying pathologies and improve treatment decisions.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University of Tübingen, Department of Neurodegenerative Disease, Hertie-Institute for Clinical Brain Research, and Center for Neurology, Tübingen, Germany (GRID:grid.10392.39) (ISNI:0000 0001 2190 1447); German Center of Neurodegenerative Diseases (DZNE), Tübingen, Germany (GRID:grid.424247.3) (ISNI:0000 0004 0438 0426); University of Tübingen, Department of Psychiatry and Psychotherapy, Tübingen, Germany (GRID:grid.10392.39) (ISNI:0000 0001 2190 1447); Center for Rare Diseases (ZSE), Tübingen, Germany (GRID:grid.10392.39)
2 University of Tübingen, Department of Psychiatry and Psychotherapy, Tübingen, Germany (GRID:grid.10392.39) (ISNI:0000 0001 2190 1447); University of Tübingen, Department of Epileptology, Hertie-Institute for Clinical Brain Research, and Center for Neurology, Tübingen, Germany (GRID:grid.10392.39) (ISNI:0000 0001 2190 1447)
3 University of Tübingen, Department of Psychiatry and Psychotherapy, Tübingen, Germany (GRID:grid.10392.39) (ISNI:0000 0001 2190 1447)
4 University of Tübingen, Department of Neurodegenerative Disease, Hertie-Institute for Clinical Brain Research, and Center for Neurology, Tübingen, Germany (GRID:grid.10392.39) (ISNI:0000 0001 2190 1447); University of Tübingen, Department of Psychiatry and Psychotherapy, Tübingen, Germany (GRID:grid.10392.39) (ISNI:0000 0001 2190 1447)
5 University of Tübingen, Department of Psychiatry and Psychotherapy, Tübingen, Germany (GRID:grid.10392.39) (ISNI:0000 0001 2190 1447); University of Tübingen, Department for General Neurology and Stroke, Hertie-Institute for Clinical Brain Research, and Center for Neurology, Tübingen, Germany (GRID:grid.10392.39) (ISNI:0000 0001 2190 1447)
6 University of Tübingen, Department of Psychiatry and Psychotherapy, Tübingen, Germany (GRID:grid.10392.39) (ISNI:0000 0001 2190 1447); University of Freiburg, Department of Neurology and Neuroscience, Medical Center, Breisgau, Germany (GRID:grid.5963.9)
7 University of Tübingen, Department of Neurodegenerative Disease, Hertie-Institute for Clinical Brain Research, and Center for Neurology, Tübingen, Germany (GRID:grid.10392.39) (ISNI:0000 0001 2190 1447); Center for Rare Diseases (ZSE), Tübingen, Germany (GRID:grid.10392.39)